Abstract Efforts to block the mitogen-activated protein kinase (MAPK) pathway for colorectal cancer (CRC) therapy are challenged by frequent oncogenic mutations of its upstream genes, robust extracellular signal-regulated kinase (ERK) reactivation and difficulty in tumor-selective targeting without compromising the physiological processes of normal cells. Deeper insight into the precise mechanism of ERK regulation could help develop potential therapeutic strategies.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Tihui
Contact Tihui, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack